Innovate Biopharma

Raleigh, United States Founded: 2012 • Age: 14 yrs
Small molecule drugs and imaging agent for GI disorders
Request Access

About Innovate Biopharma

Innovate Biopharma is a company based in Raleigh (United States) founded in 2012.. Innovate Biopharma has raised $48.58 million across 12 funding rounds. Innovate Biopharma has completed 1 acquisition, including RDD Pharma. Innovate Biopharma offers products and services including INN-202, INN-217, INN-289, and INN-108. Innovate Biopharma operates in a competitive market with competitors including Ironwood Pharma, ImaginAb, RedHill Biopharma, Alcresta and Seed, among others.

  • Headquarter Raleigh, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Medical Devices & Diagnostics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $48.58 M (USD)

    in 12 rounds

  • Latest Funding Round
    $2.75 M (USD), Debt – Conventional

    Jan 17, 2020

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Innovate Biopharma

Innovate Biopharma offers a comprehensive portfolio of products and services, including INN-202, INN-217, INN-289, and INN-108. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Targets celiac disease treatment in Phase 3 trials.

Addresses nonalcoholic steatohepatitis in early clinical stages.

Focuses on Crohn’s disease subset in Phase 1 trials.

Treats ulcerative colitis and other inflammatory disorders.

Funding Insights of Innovate Biopharma

Innovate Biopharma has successfully raised a total of $48.58M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2.75 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 12
  • Last Round Debt – Conventional — $2.8M
  • First Round

    (19 Jun 2013)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2020 Amount Debt – Conventional - Innovate Biopharma Valuation

investors

May, 2019 Amount Post-IPO - Innovate Biopharma Valuation

investors

May, 2019 Amount Post-IPO - Innovate Biopharma Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investments & Acquisitions by Innovate Biopharma

Innovate Biopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include RDD Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Developing targeted therapeutics and delivery systems for anorectal and GI disorders
2008
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Innovate Biopharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Innovate Biopharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Innovate Biopharma

Innovate Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, ImaginAb, RedHill Biopharma, Alcresta and Seed, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
domain founded_year HQ Location
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
domain founded_year HQ Location
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
domain founded_year HQ Location
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
domain founded_year HQ Location
Synbiotics are developed for simulating the gut microbiome.
domain founded_year HQ Location
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Innovate Biopharma

When was Innovate Biopharma founded?

Innovate Biopharma was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is Innovate Biopharma located?

Innovate Biopharma is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.

Is Innovate Biopharma a funded company?

Innovate Biopharma is a funded company, having raised a total of $48.58M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $8.74M, raised on Jun 19, 2013.

What does Innovate Biopharma do?

Innovate Biopharma was founded in 2012 in Raleigh, United States, as a clinical-stage biopharmaceutical company specializing in gastroenterology. The pipeline features INN-202, a tight junction regulator in phase 3 trials for celiac disease, and INN-108, a small molecule in phase 2 for inflammatory bowel disorders and mild to moderate ulcerative colitis. An imaging agent, INN-329 (secretin), is also advanced in phase 3 trials with MRCP for non-invasive pancreaticobiliary assessment.

Who are the top competitors of Innovate Biopharma?

Innovate Biopharma's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.

What products or services does Innovate Biopharma offer?

Innovate Biopharma offers INN-202, INN-217, INN-289, and INN-108.

How many acquisitions has Innovate Biopharma made?

Innovate Biopharma has made 1 acquisition, including RDD Pharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available